Literature DB >> 28597183

Discrepancies between NCCN and ESMO guidelines in the management of anal cancer: a qualitative review.

Natalie Johnson1, Gianluca Pellino2, Constantinos Simillis2, Shengyang Qiu1, Stella Nikolaou2, Daniel L Baird2, Shahnawaz Rasheed3,2, Paris P Tekkis1,3,2, Christos Kontovounisios4,5,6.   

Abstract

There is an ever-growing need, with the ongoing developments in research and the progress towards patient centered care, to delineate standardized protocols of management of anal cancer. However, guidelines from different societies show some degree of disagreement. This is a systematic review of the literature to identify similarities and discrepancies between the guidelines for the management of anal cancer drafted by the European Society for Medical Oncology (ESMO) and by the National Comprehensive Cancer Network (NCCN). We found essentially similar management for investigation, diagnosis, chemotherapy regimens, and radiotherapy doses in both ESMO and NCCN recommendations in the management of anal cancer. There were few differences, which included the levels of evidence and grades of recommendations, the delineation of radiotherapy fields, and the treatment of the elderly and personalized medicine based on genetics. The follow-up regime is also marginally different in the first 2 years. Even if the observed differences may be justified by a different implementation of evidence-based medicine among different countries for particular management modalities of anal cancer, we identified the grey areas which need further study. In addition, these facets should be assessed more carefully when planning future guidelines.

Entities:  

Keywords:  Anal cancer; Discrepancies; European Society of Medical Oncology (ESMO); National Comprehensive Cancer Network (NCCN)

Mesh:

Year:  2017        PMID: 28597183     DOI: 10.1007/s13304-017-0470-8

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  7 in total

1.  Purpose of quality standards for infectious diseases. Infectious Diseases Society of America.

Authors:  P A Gross; T L Barrett; E P Dellinger; P J Krause; W J Martone; J E McGowan; R L Sweet; R P Wenzel
Journal:  Clin Infect Dis       Date:  1994-03       Impact factor: 9.079

2.  Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines.

Authors:  Thejaswi K Poonacha; Ronald S Go
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

3.  HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.

Authors:  Joel M Palefsky; Anna R Giuliano; Stephen Goldstone; Edson D Moreira; Carlos Aranda; Heiko Jessen; Richard Hillman; Daron Ferris; Francois Coutlee; Mark H Stoler; J Brooke Marshall; David Radley; Scott Vuocolo; Richard M Haupt; Dalya Guris; Elizabeth I O Garner
Journal:  N Engl J Med       Date:  2011-10-27       Impact factor: 91.245

4.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  BMJ       Date:  2009-07-21

5.  Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.

Authors:  Robert Glynne-Jones; Per J Nilsson; Carlo Aschele; Vicky Goh; Didier Peiffert; Andrés Cervantes; Dirk Arnold
Journal:  Radiother Oncol       Date:  2014-06-16       Impact factor: 6.280

6.  Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.

Authors:  D Meulendijks; L Dewit; N B Tomasoa; H van Tinteren; J H Beijnen; J H M Schellens; A Cats
Journal:  Br J Cancer       Date:  2014-08-28       Impact factor: 7.640

7.  Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.

Authors:  Govin Thind; Bal Johal; Matthew Follwell; Hagen Fritz Kennecke
Journal:  Radiat Oncol       Date:  2014-05-29       Impact factor: 3.481

  7 in total
  3 in total

1.  Endorectal Ultrasound and Magnetic Resonance Imaging for Rectal Cancer Staging: A Modern Multimodality Approach.

Authors:  Alfonso Reginelli; Alfredo Clemente; Angelo Sangiovanni; Valerio Nardone; Francesco Selvaggi; Guido Sciaudone; Fortunato Ciardiello; Erika Martinelli; Roberto Grassi; Salvatore Cappabianca
Journal:  J Clin Med       Date:  2021-02-08       Impact factor: 4.241

Review 2.  Comparing and contrasting clinical consensus and guidelines for anal intraepithelial neoplasia in different geographical regions.

Authors:  Danielle R L Brogden; Micol E E Lupi; Oliver J Warren; Christos Kontovounisios; Sarah C Mills
Journal:  Updates Surg       Date:  2021-09-04

3.  Locoregional Therapy in De novo Metastatic Breast Cancer: A Retrospective Cohort Study.

Authors:  Sun Jianna; Kong Lingjun; Feng Nana; Liu Hong; Ren Chongxi
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.